FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced interim results from its 20 patient U.S. pilot clinical trial and its 60 patient Canadian registration trial assessing the safety and efficacy of GEM OS®1 Bone Graft in foot and ankle fusion indications. Sheldon Lin, M.D., one of the U.S. clinical investigators, presented the results today at the American Orthopedic Foot and Ankle Society (AOFAS) meeting in Toronto, Canada.
